Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07 janv. 2025 08h00 HE
|
Bioventus, Inc.
DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will...
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
02 janv. 2025 08h00 HE
|
Bioventus, Inc.
DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has...
Bioventus Reports Third Quarter Financial Results
05 nov. 2024 07h30 HE
|
Bioventus, Inc.
Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* GrowthQ3 Gross Margin Expanded 200 bpsQ3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared to...
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
29 oct. 2024 07h30 HE
|
Bioventus, Inc.
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report...
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
01 oct. 2024 09h00 HE
|
Bioventus, Inc.
DURHAM, N.C., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has signed a...
Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference
07 août 2024 16h15 HE
|
Bioventus, Inc.
DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief...
Bioventus Reports Second Quarter Financial Results
06 août 2024 07h30 HE
|
Bioventus, Inc.
Q2 Revenue Advanced by 10.3%, Organic Growth* by 13.9%Q2 Gross Margin Expanded 350 bps and Adjusted Gross Margin* 180 bpsCash from Operations of $15.2 million Increased 40.5%Raising Full-Year 2024...
Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024
30 juil. 2024 07h30 HE
|
Bioventus, Inc.
DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report...
Bioventus Reports First Quarter Financial Results
07 mai 2024 07h00 HE
|
Bioventus, Inc.
Raises Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic PrioritiesAccelerated First Quarter Revenue Growth by 8.7%, Organic Growth* by 15.3%Gross...
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
29 avr. 2024 07h30 HE
|
Bioventus, Inc.
DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report...